Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Schistocytes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Schistocytes. Displaying page 1 of 1.
    EudraCT Number: 2014-001032-11 Sponsor Protocol Number: OMS721-TMA-001 Start Date*: 2014-09-30
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 2, uncontrolled, three-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombo...
    Medical condition: Three forms of thrombotic microangiopathies (TMA): - atypical hemolytic uremic syndrome (aHUS) - hematopoietic stem cell transplant (HSCT)-associated TMA - thrombotic thrombocytopenic purpura (TTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004205-26 Sponsor Protocol Number: Assente Start Date*: 2006-07-14
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO IRCCS
    Full Title: A Randomised controlled tiral to evaluate the efficacy of low molecular-weight heparin on pregnancy outcome of women with previus pregnancy complication
    Medical condition: To asses wether the treatment with LMWH in Women with previus pregnancy complications and no evidence of anatomical, endocrine, Cromosmal or immunological abnormality result in a 40 reduction in t...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10036585 SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002329-84 Sponsor Protocol Number: APHP211039 Start Date*: 2023-01-06
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP)
    Full Title: Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial.
    Medical condition: Adult patients with aHUS associated with HE and severe kidney involvement (needing dialysis or serum creatinine ≥ 354µM).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10079840 Atypical haemolytic uraemic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004972-49 Sponsor Protocol Number: CLFG316X2202 Start Date*: 2016-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant ass...
    Medical condition: Transplant associated microangiopathy (TAM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10050444 Microangiopathy NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001940-36 Sponsor Protocol Number: TAK-755-2001 Start Date*: 2023-02-13
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombo...
    Medical condition: immune-mediated thrombotic thrombocytopenic purpura (iTTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000144-61 Sponsor Protocol Number: ALXN1210-TMA-313 Start Date*: 2020-08-17
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
    Medical condition: Hematopoietic stem cell transplant-associated thrombotic microangiopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006094-26 Sponsor Protocol Number: CTP_STX005/STX005EXT Start Date*: 2012-02-10
    Sponsor Name:Thallion Pharmaceuticals Inc
    Full Title: A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (caStx1) and 2 (caStx2) Administered Concomitantly to Children with Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody ...
    Medical condition: Prevention of Shiga toxin-mediated complications resulting from Shiga toxin producing bacterial infections.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10019515 Hemolytic uremic syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-000761-16 Sponsor Protocol Number: ALXN1210-TMA-314 Start Date*: Information not available in EudraCT
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy...
    Medical condition: hematopoietic stem cell transplant-associated thrombotic microangiopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001098-42 Sponsor Protocol Number: ALX0681-C301 Start Date*: 2015-08-27
    Sponsor Name:Ablynx NV
    Full Title: A Phase III double-blind, randomized, parallel group, multicenter placebo-controlled trial to study the efficacy and safety of caplacizumab in patients with acquired thrombotic thrombocytopenic pur...
    Medical condition: Acquired Thrombotic thrombocytopenic purpura
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) ES (Completed) AT (Completed) DE (Completed) HU (Completed) NL (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001177-31 Sponsor Protocol Number: EFC16521 Start Date*: 2022-08-29
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-m...
    Medical condition: Thrombotic Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002057-11 Sponsor Protocol Number: OMS721-HUS-002 Start Date*: 2017-09-15
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents.
    Medical condition: Atypical Hemolytic Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10019515 Hemolytic uremic syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003775-35 Sponsor Protocol Number: SHP655-201 Start Date*: 2019-07-03
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficac...
    Medical condition: acquired thrombotic thrombocytopenic purpura (aTTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043648 Thrombotic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003157-27 Sponsor Protocol Number: Sobi.PEGCET-201 Start Date*: 2021-12-17
    Sponsor Name:SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Full Title: An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (...
    Medical condition: Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006953-41 Sponsor Protocol Number: C08-002B Start Date*: 2009-08-19
    Sponsor Name:ALEXION PHARMACEUTICALS, INC.
    Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)
    Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapyresistant Atypical Hemolytic-Uremic Syndrome (aHUS).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018932 Haemolytic uraemic syndrome LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002727-38 Sponsor Protocol Number: OMS721-HCT-002 Start Date*: Information not available in EudraCT
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant...
    Medical condition: Thrombotic microangiopathies following haematopoietic stem cell transplant
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10064477 Coagulopathies and bleeding diatheses (excl thrombocytopenic) HLGT
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    20.0 10005329 - Blood and lymphatic system disorders 10053567 Coagulopathies HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Completed) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006955-28 Sponsor Protocol Number: C08-003B Start Date*: 2009-08-19
    Sponsor Name:ALEXION PHARMACEUTICALS, INC.
    Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
    Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapysensitive Atypical Hemolytic-Uremic Syndrome (aHUS).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018932 Haemolytic uraemic syndrome LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006952-23 Sponsor Protocol Number: C08-002A Start Date*: 2009-08-19
    Sponsor Name:ALEXION PHARMACEUTICALS, INC.
    Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)
    Medical condition: Adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018932 Haemolytic uraemic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006954-17 Sponsor Protocol Number: C08-003A Start Date*: 2009-06-18
    Sponsor Name:ALEXION PHARMACEUTICALS, INC.
    Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
    Medical condition: Adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018932 Haemolytic uraemic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:32:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA